SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME

The present invention relates to: a substituted thiazolidinedione derivative compound having a novel structure acting as a sterol regulatory element-binding protein-1 (SREBP1) inhibitor, a hydrate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing...

Full description

Saved in:
Bibliographic Details
Main Authors PARK, Jong Min, KIM, Jun-Kyum, MIN, Ju-sik, LEE, Su-Jeong, KIM, Sang Bum, KIM, Sung Jin, CHOI, Jia, MIN, Kyungim, KIM, Dong-Hyun, KIM, Jina, PARK, Jeong-Eun, JEONG, Minseon, CHOI, Hyo-Jung, LEE, Sungwoo, KIM, Eun-Jung, CHO, Sung Jin, LIM, Ji-youn, HAM, Seok Won, KIM, Nayeon, KWON, Oh-Bin, PARK, Cheol-Kyu, KIM, Suhui, JEONG, Hyeon Ju, CHIN, Jungwook, KWON, Sugyeong, AN, Hongchan, HWANG, Ji Sun, PARK, Min Gi, HWANG, Hayoung, JUNG, Kyung Jin
Format Patent
LanguageEnglish
French
Korean
Published 29.06.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to: a substituted thiazolidinedione derivative compound having a novel structure acting as a sterol regulatory element-binding protein-1 (SREBP1) inhibitor, a hydrate thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition for preventing or treating cancer, comprising same as an active ingredient. La présente invention concerne : un composé dérivé de thiazolidinedione substitué ayant une nouvelle structure agissant en tant qu'inhibiteur de protéine-1 de liaison à un élément régulateur de stérol (SREBP1), un hydrate de celui-ci, ou un sel pharmaceutiquement acceptable de celui-ci ; et une composition pharmaceutique pour prévenir ou traiter le cancer, le comprenant en tant que principe actif. 본 발명은 SREBP1(sterol regulatory element-binding protein-1) 저해제로 작용하는 신규 구조의 치환된 티아졸리딘디온 유도체 화합물, 이의 수화물 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 이를 포함하는 암의 예방 또는 치료용 약학적 조성물에 관한 것이다.
Bibliography:Application Number: WO2022KR20728